News

KIT Mutation Testing Yields Survival Benefit for GIST Patients

09/03/2020

A long-term analysis of patients with localized and metastatic GIST determined there were survival differences associated with KIT mutation testing and other clinical variables.

A long-term analysis of patients...

09/03/2020

Oncology

News

Avapritinib Active Against Unresectable PDGFRA D842V-Mutant GIST

07/17/2020

Avapritinib had a manageable safety profile and demonstrated activity in patients with PDGFRA D842V-mutant GIST in the NAVIGATOR trial.

Avapritinib had a manageable...

07/17/2020

Oncology

News

Extended Imatinib Therapy Post-Resection Improves Survival in High-Risk GIST

06/09/2020

After a median follow-up of 10 years, 3 years of adjuvant imatinib was associated with significantly improved RFS and OS compared with 1 year of imatinib, after surgery, in patients with high risk-GIST.

After a median follow-up of 10...

06/09/2020

Oncology

News

FDA Approves Ripretinib for Pretreated Adults With Advanced GIST

05/15/2020

The FDA has approved ripretinib for the treatment of adults with advanced GIST who have received therapy with ≥3 or more kinase inhibitors, including imatinib.

The FDA has approved ripretinib...

05/15/2020

Oncology

News

OS More Affected by Tumor Rupture Than Surgery Type in GIST

04/07/2020

OS in patients with GIST is impacted more by tumor rupture than quality of surgery or treatment with adjuvant imatinib, a substudy has shown.

OS in patients with GIST is...

04/07/2020

Oncology

News

Better Survival With Complete Resection, Presurgery Imatinib for Giant GIST

03/16/2020

Presurgery imatinib or R0 resection were the best treatment options for patients with giant GIST in a retrospective study.

Presurgery imatinib or R0...

03/16/2020

Oncology

News

NGS of Plasma ctDNA Valuable for Detecting KIT Mutations in Metastatic GIST

02/10/2020

Plasma NGS was found to be valuable for detecting KIT primary and secondary mutations in patients with metastatic GIST, study findings show.

Plasma NGS was found to be...

02/10/2020

Oncology

News

Therapeutic Monitoring of Sunitinib Shows Potential in Adults With GIST and Metastatic RCC

01/24/2020

Review findings support the use of sunitinib dose modification guided by therapeutic drug monitoring in certain patients with RCC and GIST.

Review findings support the use...

01/24/2020

Oncology

News

FDA Approves Avapritinib as First Targeted Therapy for Rare GIST Mutation

01/09/2020

The FDA has approved avapritinib for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation.

The FDA has approved avapritinib...

01/09/2020

Oncology

News

5-Year Adjuvant Imatinib Yields Positive Outcomes, Low Adherence Rates in Patients With Primary GIST

12/20/2018

Extended duration of adjuvant therapy with imatinib shows efficacy in certain patients with gastrointestinal stromal tumors, but adherence to therapy remains a challenge.

Extended duration of adjuvant...

12/20/2018

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology